Brain Wealthy
    What's Hot

    Little Celebrities on Campus Who Will Change College Life | By Reid Zura | Starship Technologies | June 2023

    June 5, 2023

    Inclusiveness in Practice: Starship Technologies Proudly Deployed in LA | By Reid Zura | Starship Technologies | June 2023

    June 1, 2023

    Global Accessibility Awareness Day: Building Accessibility into Technology | By Ed Lovelock | Starship Technologies | May 2023

    May 18, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

      February 2, 2023

      How anxiety came to dominate the big business of medical marijuana cards in Pa.

      February 2, 2023

      How to Reduce Anxiety in Stressful Situations

      February 2, 2023

      The cat in boots The last wish taught me about anxiety

      February 2, 2023

      Inseparable cat trio with ‘separation anxiety brothers’ find new home

      February 2, 2023
    • Emotion

      Leigh-Anne Pinnock shares emotional post about embarking on her solo career

      February 2, 2023

      Ontario paramedic emotional during last radio call

      February 2, 2023

      A Pianist Faces Death and Recorded Music of Unspeakable Emotions

      February 2, 2023

      Return of home post linking Gichaara to ancestors is emotional for north coast nation

      February 2, 2023

      Mother of two sues New York school district for ‘mental distress’ caused by mask enforcement

      February 2, 2023
    • Neurology

      Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

      February 2, 2023

      REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

      February 2, 2023

      Aducanumab for the treatment of Alzheimer’s disease

      February 2, 2023

      Potential for Effective Comparative Studies and Treatment Approval in Epilepsy Care: Anup Patel, MD

      February 2, 2023

      Head injury does not predict memory impairment in NFL retirees, UT Southwestern study shows: Newsroom

      February 2, 2023
    • Sleep

      Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

      February 2, 2023

      Get a better night’s sleep with better pillows from The Pillow Bar in Dallas

      February 2, 2023

      Is it okay to sleep with a necklace on?

      February 2, 2023

      Does tart cherry juice improve sleep?

      February 2, 2023

      Social Jet Lag, Sleep Chronotypes, and Why We Gotta Close Our Eyes and Embrace It

      February 2, 2023
    • Brain Research

      spark!Talk – video available online

      February 2, 2023

      Studies have found that obesity-related neurodegeneration mimics Alzheimer’s disease.newsroom

      February 2, 2023

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023
    Brain Wealthy
    Home»Neurology»FDA accused of ‘improperly’ cooperating with Biogen to treat Alzheimer’s disease
    Neurology

    FDA accused of ‘improperly’ cooperating with Biogen to treat Alzheimer’s disease

    brainwealthy_vws1exBy brainwealthy_vws1exDecember 30, 2022No Comments4 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    December 30, 2022

    Read in 3 minutes


    Add topic to email alert

    Get an email when new articles are posted

    Enter your email address to receive an email when new articles are posted .

    Your request could not be processed. Please try again later. If this issue persists, please contact us at customerservice@slackinc.com.

    A congressional inquiry found the FDA’s interactions with Biogen to be “unusual and non-protocol” and that the two “inappropriately cooperated on documentation” prior to Aduhelm’s approval for Alzheimer’s disease. ” it turned out.

    Additionally, according to the executive summary of the study, Biogen, the maker of Aduhelm (aducanumab), initially set an “unreasonably high price” for the drug in order to “make history” for the company. According to internal documents, Biogen initially priced Aduhelm at $56,000 annually “despite its lack of demonstrated clinical benefit.”

    Source: Adobe Stock.

    A congressional investigation found that the FDA’s interactions with Biogen were “unusual and non-protocol” and that the two had “improperly cooperated” on documents before approving AD’s Aduhelm. It has been with. Source: Adobe Stock

    The findings of the investigation were released on Dec. 29 by the staff of the US House of Representatives’ Oversight and Reform Committee and the Energy and Commerce Committee.Chairman of the Energy Commerce Commission Frank Parone Jr. (DN.J.) has released a statement regarding the report.

    “This report chronicles the extraordinary FDA review process and corporate greed that preceded the FDA’s controversial decision to grant accelerated approval to Aduhelm,” said Pallone. “While we all support the search for new treatments and cures to combat devastating diseases like Alzheimer’s disease, the FDA’s independence and scientific rigor over protocols guarantee it.” convenience must not be a priority, and patient safety and efficacy must remain at the heart of our country’s regulatory review process.”

    Aduhelm was granted accelerated approval by the FDA on June 7, 2021. On the same day, the FDA called for a federal investigation into the approval of the Biogen treatment.

    A congressional study found that the FDA and Biogen held at least 115 meetings, phone calls and email exchanges over a 12-month period. More than 40 working group meetings were held, according to the report, but not all were properly documented.

    According to a congressional investigation, “FDA’s own internal review of the FDA’s approval process for Aduhelm found the degree of cooperation between FDA and Biogen to be atypical and, in some respects, beyond the norm.” It turned out.”

    Additionally, the report says the FDA “suddenly” changed the course of the traditional approval process, accelerating Aduhelm’s approval after just three weeks of review. Authorities initially considered him under the conventional approval process used for most drugs.

    The investigation found that the move to accelerated approval only occurred after the April 7, 2021 FDA expert meeting, which “brought unfavorable feedback on Aduhelm’s previous approval.” On April 28, 2021, the FDA notified Biogen that Aduhelm will be considered for accelerated approval.

    The report also says the FDA has approved Aduhelm for a wide range of indications, and Biogen has, despite the lack of clinical data. The agency approved He Aduhelm for the treatment of “Alzheimer’s patients.” This is a much broader population than Biogen studied in clinical trials, and included people with mild cognitive impairment and mild dementia.

    In 2023, the FDA plans to meet and discuss two other treatments for Alzheimer’s disease and related dementias. Biogen and Eisai are developing another Alzheimer’s drug, lecanemab, which reduced cognitive decline by 27%. Eli Lilly recently announced that its treatment, donanemab, met its primary and secondary endpoints in a Phase 3 trial.

    References:

    Aduhelm investigation. https://oversight.house.gov/sites/democrats.oversight.house.gov/files/Final_Document_Packet-Biogen_UPDATED_Redacted.pdf. Published December 29, 2022. Accessed 30 December 2022.

    FDA expedites approval of drugs for Alzheimer’s disease. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug. Published June 7, 2021. Accessed December 30, 2022.

    Lilly shares positive data for donanemab in the first active controlled trial in early symptomatic Alzheimer’s disease. https://investor.lilly.com/news-releases/news-release-details/lilly-shares-positive-donanemab-data-first-active-comparator. Published November 30, 2022. Accessed 30 December 2022.

    Maloney and Pallone released a staff report on the review, approval and pricing of Biogen’s Alzheimer’s drug Aduhelm. https://energycommerce.house.gov/newsroom/press-releases/maloney-and-palllone-release-staff-report-on-review-approval-and-pricing-of. Accessed 30 December 2022.

    The cost of Aduhelm’s approval: An investigation into the FDA’s unusual review process and Biogen’s aggressive launch plans. https://energycommerce.house.gov/sites/democrats.energycommerce.house.gov/files/documents/Final%20Aduhelm%20Report_12.29.22.pdf. Published December 29, 2022. Accessed 30 December 2022.


    Add topic to email alert

    Get an email when new articles are posted

    Enter your email address to receive an email when new articles are posted .

    Your request could not be processed. Please try again later. If this issue persists, please contact us at customerservice@slackinc.com.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleManaging mental health at holiday family gatherings
    Next Article Emotional Kirk Ferenc thanking seniors
    brainwealthy_vws1ex
    • Website

    Related Posts

    Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

    February 2, 2023

    REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

    February 2, 2023

    Aducanumab for the treatment of Alzheimer’s disease

    February 2, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.